Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective.

Ghaddar A, Khandaqji S, Abbass Z.

Subst Abuse Treat Prev Policy. 2018 Apr 19;13(1):14. doi: 10.1186/s13011-018-0151-8.

2.

Increasing diversion of methadone in Vancouver, Canada, 2005-2015.

Reddon H, Ho J, DeBeck K, Milloy MJ, Liu Y, Dong H, Ahamad K, Wood E, Kerr T, Hayashi K.

J Subst Abuse Treat. 2018 Feb;85:10-16. doi: 10.1016/j.jsat.2017.11.010. Epub 2017 Nov 28.

PMID:
29291766
3.

Advances in the delivery of buprenorphine for opioid dependence.

Rosenthal RN, Goradia VV.

Drug Des Devel Ther. 2017 Aug 28;11:2493-2505. doi: 10.2147/DDDT.S72543. eCollection 2017. Review.

4.

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S.

JAMA Psychiatry. 2017 Sep 1;74(9):894-902. doi: 10.1001/jamapsychiatry.2017.1874.

PMID:
28655025
5.

Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.

Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A.

Ther Adv Psychopharmacol. 2017 Mar;7(3):119-134. doi: 10.1177/2045125316681984. Epub 2016 Dec 19. Review.

6.

Validity of Self-Reported Drug Use Information Among Pregnant Women.

Garg M, Garrison L, Leeman L, Hamidovic A, Borrego M, Rayburn WF, Bakhireva L.

Matern Child Health J. 2016 Jan;20(1):41-7. doi: 10.1007/s10995-015-1799-6.

7.

Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions.

Bouquié R, Wainstein L, Pilet P, Mussini JM, Deslandes G, Clouet J, Dailly E, Jolliet P, Victorri-Vigneau C.

PLoS One. 2014 Dec 4;9(12):e113991. doi: 10.1371/journal.pone.0113991. eCollection 2014.

8.

Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.

Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.

Drug Alcohol Depend. 2013 Dec 1;133(2):376-82. doi: 10.1016/j.drugalcdep.2013.06.024. Epub 2013 Jul 31.

9.

Long term Suboxone™ emotional reactivity as measured by automatic detection in speech.

Hill E, Han D, Dumouchel P, Dehak N, Quatieri T, Moehs C, Oscar-Berman M, Giordano J, Simpatico T, Barh D, Blum K.

PLoS One. 2013 Jul 9;8(7):e69043. doi: 10.1371/journal.pone.0069043. Print 2013. Erratum in: PLoS One. 2013;8(8):doi/10.1371/annotation/be0b3a26-c1bc-4d92-98c1-c516acc8dcf2. Barh, Debmalya [added].

10.

Provision of opioid substitution therapy services in Australian pharmacies.

Chaar BB, Hanrahan JR, Day C.

Australas Med J. 2011;4(4):210-6. doi: 10.4066/AMJ.2011.706. Epub 2011 Apr 30.

11.

Self-reported psychopathology and health-related quality of life in heroin users treated with methadone.

Chen YZ, Huang WL, Shan JC, Lin YH, Chang HC, Chang LR.

Neuropsychiatr Dis Treat. 2013;9:41-8. doi: 10.2147/NDT.S37284. Epub 2012 Dec 27.

12.

Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds.

Whelan PJ, Remski K.

J Neurosci Rural Pract. 2012 Jan;3(1):45-50. doi: 10.4103/0976-3147.91934.

13.

The nature of methadone diversion in England: a Merseyside case study.

Duffy P, Baldwin H.

Harm Reduct J. 2012 Jan 13;9:3. doi: 10.1186/1477-7517-9-3.

14.

Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence.

Gray TR, Dams R, Choo RE, Jones HE, Huestis MA.

Forensic Sci Int. 2011 Mar 20;206(1-3):98-102. doi: 10.1016/j.forsciint.2010.06.031. Epub 2010 Jul 27.

Supplemental Content

Support Center